Key Takeaways
- Superpower Peptides: Superpower opened pre-orders on October 30, 2026 for BPC-157 and TB-500 at $149 a month and MOTS-c at $199 a month, with a target ship date of late November.
- The legal opening: HHS said on October 28 that it does not intend to act against pharmacies compounding six peptides. The policy is not FDA approval.
- The evidence: Superpower's own page says research on BPC-157 in people is limited. HHS's policy says FDA's drug center recommended against listing all three launch peptides.
- The price: By a comparison Superpower's co-founder endorsed, its BPC-157 costs about $10 per mg against $4.40 on the gray market.
Superpower, a San Francisco health startup, opened pre-orders on October 30, 2026 for prescribed BPC-157 and TB-500 at $149 a month and MOTS-c at $199 a month, two days after the Department of Health and Human Services said it does not intend to act against pharmacies compounding those peptides.
What Superpower Peptides Costs and Who Can Buy It
Buyers pay the first month when they pre-order, and Superpower reviews each prescription request when it is ready to ship, its page says. Anyone not approved gets a full refund. Approved buyers are charged again 30 days later, then every 30 days. By WYDE's arithmetic, that comes to about $1,800 a year for BPC-157 or TB-500 and about $2,400 for MOTS-c. A blood test and membership, which Superpower values at $199, are included. Epitalon, an oral BPC pill and a Semax nasal spray are on a waitlist.
BPC-157 is not available in all 50 states and is not eligible for HSA or FSA funds, the BPC-157 page says. A licensed clinician decides eligibility after reviewing a buyer's intake and labs, and Superpower calls the $149 limited-time early access pricing.
The HHS Peptide Policy Behind the Launch
The notice, signed by Health Secretary Robert F. Kennedy Jr. and filed on October 28, says HHS does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding the listed peptides, the Federal Register shows. The six are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. "Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed," the HHS notice says. HHS may revisit the policy if a safety signal or quality problem arises.
The conditions include FDA-registered ingredient makers, certificates of analysis and reporting of serious adverse events, and the policy does not add the peptides to the official compounding list or amount to FDA approval, the law firm Foley & Lardner wrote. Superpower's page says oral forms need evidence of adequate absorption in humans. In May, co-founder Max Marchione told The San Francisco Standard that the company was waiting for the FDA. The opening came from HHS instead.
What FDA's Drug Center and Critics Say About These Peptides
HHS's own policy document says FDA's Center for Drug Evaluation and Research recommended against listing BPC-157, TB-500 and MOTS-c, while FDA's advisory committee voted in favor. On BPC-157, Superpower's page says: "Research in people is still limited, and its safety and effectiveness have not been established." Related WYDE coverage: Superpower's 152-Peptide Library Includes BPC-157.
"By allowing unproven and potentially unsafe peptides to be manufactured, marketed and prescribed without concern about potential federal enforcement actions, Kennedy has undermined the FDA and threatened public health," Dr. Robert Steinbrook of Public Citizen said, NPR reported. Scott Brunner of the Alliance for Pharmacy Compounding called the policy a more accountable alternative to the gray market but warned that dispensing may take time. One pharmacy president told NPR he does not think all small compounders together could meet demand.
Superpower's Price Against the Gray Market
"Superpower peptides are higher price than grey market because we are doing things right," Marchione wrote on X, citing clinician prescribing, US-licensed pharmacies, testing and blood work. Jesse Morse, a physician, put Superpower's BPC-157 at $150 for 15 mg, or $10 per mg, against $44 for 10 mg, or $4.40 per mg, for research-use-only product, a comparison Marchione endorsed. By WYDE's arithmetic, that is about 2.3 times the gray-market price per mg. HHS said the policy should discourage research-use-only peptides from foreign manufacturers, Foley & Lardner wrote.
People Also Ask
How much does Superpower Peptides cost?
Superpower Peptides costs $149 a month for BPC-157 or TB-500 and $199 a month for MOTS-c, at what Superpower calls early access pricing. The first month is charged at pre-order and refunded if no prescription is approved.
Is BPC-157 FDA-approved?
No. Superpower's page says compounded BPC-157 is not FDA-approved, and the law firm Foley & Lardner wrote that the October 28 HHS policy does not amount to FDA approval.
Do you need a prescription for Superpower Peptides?
Yes. Superpower says a patient-specific prescription is required and that a licensed clinician decides eligibility after reviewing a buyer's intake and labs.
When will Superpower Peptides ship?
Superpower's target ship date is late November 2026. Pre-orders opened on October 30, 2026.
Sources: Superpower, Federal Register, HHS, NPR, Foley & Lardner, The San Francisco Standard.